We hypothesized that perioperative ketamine administration would modify acute central sensitization following amputation and hence reduce the incidence and severity of persistent post-amputation pain (both phantom limb and stump pain). In a randomized, controlled trial, 45 patients undergoing above-or below-knee amputation received ketamine 0.5 mg.kg -1 or placebo as a pre-induction bolus followed by an intravenous infusion of ketamine 0.15 mg.kg -1 .h -1 or normal saline for 72 hours postoperatively. Both groups received standardized general anaesthesia followed by patient-controlled intravenous morphine. The surface area of allodynia over the stump was mapped at days 3 and 6. Postamputation pain was assessed at days 3 and 6 and at 6 months postoperatively.
Studies over the past 20 years have reported the incidence of phantom limb pain after amputation to be 49 to 88% [1] [2] [3] [4] [5] [6] . The onset is generally early, with 75% of patients developing pain within the first few days after amputation. The frequency and duration of attacks tends to reduce with time, although prevalence and intensity remain constant 5 . The pain is typically intermittent and located in the distal section of the limb. Stump pain is common in the immediate postoperative phase. If stump pain continues beyond the first postoperative week it tends to persist and may be described in neuropathic terms 7 . Some authors have noted a correlation between the presence of stump pain and phantom pain 6,8,9 . In this study we use the term "post-amputation pain" to include both phantom limb pain and stump pain. Phantom limb pain is, by definition, neuropathic in origin. With stump pain, nociceptive factors may predominate early but neuropathic mechanisms may be responsible when pain persists. Peripheral, spinal cord and cerebral factors have all been implicated in the development of post-amputation pain, although their relative importance is unclear. It has been proposed that in the generation of postamputation pain, the first events occur in the periphery with a subsequent cascade sweeping centrally, recruiting spinal and, ultimately, cortical brain structures 7 . Reduction of pain in the perioperative period may therefore prevent the evolution of this process and thus minimize the risk of progression to persistent pain. Activation of N-methyl-D-aspartate (NMDA) receptors at a spinal cord level is part of this process of amplification. Ketamine can modulate the process by blockade of the NMDA receptors 10 and therefore has the potential to reduce the development of persistent post-surgical pain 11 .
The evidence base regarding prevention of postamputation pain is incomplete. Several studies reporting positive results from epidural analgesia have methodological problems [12] [13] [14] [15] and other studies have failed to confirm the findings 16, 17 . A pilot study has supported a possible role for intravenous ketamine infusion in the prevention of severe phantom limb pain 18 and there have also been reports of shortterm benefit from ketamine in the treatment of established phantom limb pain [19] [20] [21] . However, despite growing understanding of the mechanistic basis of post-amputation pain and the publication of a number of clinical trials, the prevention of both phantom limb pain and stump pain remains a significant challenge. This study is, to our knowledge, the first randomized, controlled trial to investigate the role of intravenous ketamine infusion in post-amputation pain. Our aim was to assess whether ketamine could modify the acute central sensitization process and hence reduce the incidence and severity of persistent post-amputation pain six months later.
Materials and Methods
After obtaining approval from our regional ethics committee, we performed a randomized, doubleblind, placebo-controlled trial of 45 patients presenting for above-or below-knee amputation. Informed consent was obtained in all cases. All patients were recruited from one tertiary referral hospital and had lower limb amputation because of peripheral vascular disease, cancer or chronic infection. Patients were excluded if they were unable to give informed consent, had severe ischaemic heart disease or were considered unsuitable for general anaesthesia with endotracheal intubation. Patients were randomized (via a random number generator) to receive either ketamine (ketamine group KG) or normal saline (placebo group PG).
The patient, anaesthetist, Acute Pain Service (APS) personnel, ward staff and investigators were blinded to the contents of the trial solution.
All patients received a standardized general anaesthetic (midazolam 0.025 mg.kg -1 , morphine 0.05 mg.kg -1 , thiopentone 1-5 mg.kg -1 , vecuronium 0.1 mg.kg -1 or atracurium 0.5 mg.kg -1 , endotracheal intubation and intermittent positive pressure ventilation with oxygen, nitrous oxide and isoflurane). After induction additional opioids were given at the anaes-thetist's discretion. The KG patients received a pre-induction intravenous (IV) bolus of ketamine 0.5 mg.kg -1 , followed immediately by IV infusion at 0.15 mg.kg -1 .h -1 . Control (PG) patients received a pre-induction IV bolus of normal saline, followed by IV infusion. Trial solutions were continued for three days postoperatively. If side-effects considered attributable to ketamine occurred (vivid dreams, hallucinations or confusion), the infusion rate was halved. If side-effects then continued or were severe, the infusion was ceased. All patients received patientcontrolled analgesia (PCA) with morphine (1 mg bolus, 5 min lockout). Fentanyl was available in the protocol as a second line opioid for cases of renal impairment or adverse reaction to morphine, however its use was not required in any of the trial patients. APS staff visited patients daily until cessation of parenteral analgesics. The development of significant phantom limb pain after day 3 was treated with amitriptyline and/or sodium valproate.
Each patient was followed up using a structured questionnaire, by either of two investigators (AAB or CH) on postoperative days 3 and 6 and via telephone interview at six months. For the majority of patients a single investigator followed their individual case through and collected all data. On day 3, opioid consumption in the first 24 and 72 hours postoperatively was recorded. Complications and patient satisfaction were noted. At follow-up visits, patients were asked about phantom or stump pain in the previous 24 hours. Each was asked to rate their highest, lowest, usual and current level of pain using a numerical rating scale (NRS), with 0 representing no pain and 10 the worst pain imaginable.
Assessment of central sensitization was undertaken at day 3 and 6. We used von Frey monofilaments (Stoelting, Illinois) to assess sensory response as a measure of central sensitization. A series of 20 monofilaments of graduated diameter (1.65-6.65 units) can be used to produce standardized stimuli and measure touch and pain thresholds. Each monofilament is labeled according to the log 10 of force (grams) applied. Normally, all monofilaments are perceived as touch stimuli. In areas of allodynia, application of a monofilament may elicit pain. We measured touch and pain thresholds at a standardized point on the anterior stump surface 5 cm from the surgical incision. The next largest monofilament from that perceived as painful was then used to map out the surface area of allodynia over the stump. The area was traced onto graph paper. An "allodynia index" was calculated as the surface area of allodynia divided by the patient's calculated body surface area. This technique is an adaptation of the methodology of previous authors who used a standardized von Frey monofilament [22] [23] [24] . It was designed to account for the possibility of pre-existing sensory deficit in the limb.
The unpaired t-test and Fisher's exact test were used to compare demographic details in the treatment and control groups. Fischer's exact test was used to analyse differences in the incidence of phantom and stump pain. The Mann Whitney U test was used to analyse differences between groups in pain severity, duration, sensory thresholds, morphine use, surface area of allodynia and allodynia index.
Our power calculation was based on the search for a large effect of ketamine on the incidence of phantom pain. We assumed a 70% incidence of phantom limb pain in the control group and judged a reduction to 25% in the treatment group to be of clinical significance. At 90% power this gave a recommended total sample size of 41 (G Power). Because of the anticipated withdrawal of patients over the 6 month follow-up period, we aimed to enrol 45 patients.
RESULTS

Patient characteristics at enrolment
A total of 45 patients were enrolled in the study. Twenty-two patients were randomized to KG and 23 to PG. There were no significant demographic differences between groups.
The groups were similar for the indication for amputation and for the incidence of diabetes mellitus and pre-existing peripheral neuropathy. Most patients required amputation on the basis of peripheral vascular disease. One patient had an osteosarcoma (PG), another osteomyelitis (PG), and another Charcot's arthropathy (KG). All patients except the person with Charcot's arthropathy reported preoperative pain in the limb to be amputated. The median duration of preoperative pain for the KG was six weeks (interquartile range (IQR) 50 weeks) compared with 10 weeks (IQR 31 weeks) for the PG (P=0.13). There were no significant differences between the two groups in the pain severity preoperatively. The median highest NRS was 8 (IQR 3) (KG) versus 9 (IQR 3.5) (PG, P=0.12). Most patients were using oral or parenteral opioids or compound analgesics preoperatively. Eight patients in each group were using either simple or no analgesics at the time of preoperative assessment.
Exclusions/withdrawals
Three patients were excluded shortly after randomization. One (PG) received a spinal anaesthetic, one (PG) was withdrawn after waking with uncontrollable phantom limb pain postoperatively such that an epidural technique was required and another (KG) had delayed emergence from anaesthesia. By day 3, one patient (PG) had died from a pulmonary embolus; one patient (PG) had been excluded due to an inability to use the PCA device and one (KG) had chosen to withdraw from the study. This left 39 patients (KG n=20, PG n=19) for analysis of day 3 and day 6 data. At the six-month review, five KG patients had died, leaving 15 in the group and a further three patients from PG had died, leaving 16. The patient excluded on the basis of severe pain in the recovery room requiring epidural insertion was included in the analysis of the incidence of phantom and stump pain on an intention-to-treat basis.
Central sensitization
On day 3, 17 patients in each group were able to participate in central sensitization testing using von Frey monofilaments. The median pain thresholds on the stump were 5.18 units (IQR 1.23) (KG) and 5.88 units (IQR 1.07) (PG, P=0.28). The median surface area of allodynia was 114 (IQR 261.2) cm 2 (KG) and 61.5 (IQR 178.9) cm 2 (PG, P=0.66). The median allodynia index was 58. 8 
Medication use, side-effects and patient satisfaction
There was no significant difference in median mor- There was no significant difference between groups in patient satisfaction with treatment (Figure 1) , requirement for change in the rate of trial solution or in side-effects attributable to ketamine (six in each group experienced confusion, sedation or nausea and two patients in PG received treatment with benzodiazepines). There were no significant betweengroup differences in usage of tricyclic antidepressants and/or anti-epileptic drugs. On day 3, two patients in each group were taking oral anti-neuropathic agents (P=0.99). On day 6, four KG patients and two PG patients were on oral anti-neuropathic drugs (P=0.66) and at six months this had fallen to three KG patients and one PG patient (P=0.33).
Phantom limb pain
There were no significant differences between groups in the incidence of phantom limb pain throughout the study period ( Figure 2 
Stump Pain
Incidence of stump pain is shown in Figure 3 . On day 3, 19 of 20 KG patients (95%) and 13 of 20 PG patients (65%) had stump pain (P=0.04). There were no significant differences for the remainder of the study period. On day 6, 80% (KG) and 65% (PG) reported stump pain (P=0.48). At 6 months, 47% (7 of 15 KG patients) and 35% (6 of 17 PG patients) reported stump pain (P=0.72). There were no significant differences between groups for the highest, lowest and usual severity of stump pain. On day 3 median highest NRS was 6 (IQR 4.5) (KG) and 4 (IQR 7) (PG, P=0.08). On day 6 median highest NRS was 7 (IQR 5.5) (KG) and 3 (IQR 8) (PG, P=0.23) and at 6 months 0 (IQR 5.5) and 0 (IQR 4.25) respectively (P=0.62). The incidence of "troublesome" stump pain was 27% (4 of 15 KG patients) and 25% (4 of 16 PG patients) at 6 months (P=1.0).
There were no significant differences in the duration of stump pain during the preceding 24 hours throughout the study period. On day 3 the median duration of stump pain in the preceding 24 hours was 8.5 h (IQR 11.5) (KG) and 2 h (IQR 16) (PG, P=0.36). On day 6 this duration was 2.25 h (IQR 11.5) (KG) and 1 h (IQR 8) (PG, P=0.24) and at 6 months 0 h (IQR 2) and 0 h (IQR 0.15) respectively (P=0.36).
Relationship of phantom and stump pain
There was no significant relationship throughout the study period (day 3 P=0.4, day 6 P=1.0, 6 months P=0.15, Fisher's exact test).
DISCUSSION
At the dose administered, ketamine did not alter morphine consumption, nor did it alter central sensitization as measured by surface area of allodynia. There was no difference in the incidence of stump pain at six months or in the severity of postamputation pain throughout the study period. The incidence of phantom pain at six months was 47% in ketamine group and 71% in PG, although this difference did not reach statistical significance. We used the incidence of phantom pain for our sample size calculation because this was the major outcome measure reported in previous studies. The initial power calculation was based on a desire to detect a large treatment effect of ketamine, although in retrospect the search for a moderate treatment effect would have been preferable. A number of patient withdrawals in both groups, largely due to death, also contributed to reduction in power of the study. It is therefore possible that a study of increased power could demonstrate a moderate sized treatment effect of ketamine on the incidence of phantom pain. If however, such a benefit does exist, the mechanism remains unclear and does not correlate with our measure of acute postoperative central sensitization (allodynia index).
There have been conflicting results in studies looking at the role of ketamine for the management of postoperative pain. Ketamine, either by infusion or added to patient-controlled analgesia (PCA), has been shown to reduce postoperative opioid requirement following cholecystectomy 25 , caesarean section 26 , knee surgery 27 and laparotomy 28 . Ketamine use has also been shown to reduce pain severity, in addition to opioid requirement, after major abdominal surgery 29 and microdiscectomy 30 . Others have not confirmed these results, with no change in morphine consumption and/or pain reported following abdominal surgery 31, 32 and total abdominal hysterectomy 33, 34 . The reasons for these inconsistencies are not clear. It is known that NMDA receptor antagonists are not effective against all types of pain. In animal studies they block prolonged, "wind-up", "pathological" pain but not the baseline "physiological" pain responses 35, 36 .
Whether or not ketamine produces opioid reduction may depend on the relative contribution of acute nociceptive and central sensitization components to the pain experienced. Timing may also be involved and it has been suggested that clinical benefit from NMDA receptor blockade may only occur after sufficient stimulation has occurred to open the receptor ligand gated channel 37 . However, one could also argue that once central sensitization is established, its reversal may require higher doses of ketamine and administration for a longer period.
Postoperative opioid consumption and pain severity are both compound variables influenced by other factors. In the search for more specific outcome variables, a number of measures of central sensitization have been studied. In animal work markers include c-fos expression in the dorsal horn. Inhalational anaesthesia with nitrous oxide and/or halothane does not modify c-fos expression whereas fentanyl does 38 . In human studies, postoperative sensory alteration has been used to measure central sensitization. Wilder-Smith assessed sensory thresholds after abdominal hysterectomy and found that fentanyl, ketamine and magnesium supplementation of general anaesthesia all produced central sensory inhibition. Fentanyl was the most potent, followed by ketamine and then magnesium 39 that intraoperative supplementation with fentanyl or ketamine during abdominal hysterectomy reduced postoperative wound hyperalgesia, although pain intensity was not significantly reduced 40 . A lack of correlation has also been demonstrated between reduction in allodynia or mechanical hyperalgesia around the surgical incision after abdominal hysterectomy 41 or donor nephrectomy 24 and subsequent opioid requirement. Stubhaug 24 used a methodology similar to ours and found that intravenous ketamine infusion, commencing before surgery and continuing for a three-day period, markedly reduced mechanical hyperalgesia around the wound. Both treatment and control groups received intraoperative opioids and postoperative PCA morphine. Opioid use and pain intensity were reduced in the ketamine group only in the first hours after surgery. The clinical relevance of reduction in central sensitization therefore remains unclear in terms of the acute postoperative phase.
Perioperative ketamine use has also been advocated as a possible means of preventing progression of acute pain to persistent pain. A pre-induction dose of ketamine reduces the incidence of persistent pain after modified radical breast surgery at three-and sixmonth follow-up 42 . In the post-amputation setting, a small observational study with historical controls suggested that perioperative intravenous ketamine infusion might reduce severe (NRS >3) phantom limb pain 18 . However, in view of the study design and simultaneous extensive use of regional techniques, the authors stressed the need for randomized controlled trials. Preservative-free epidural ketamine, as a preoperative bolus and continued as an infusion for 48 hours, did not alter the incidence of postamputation pain when combined with spinal/epidural bupivacaine (for anaesthesia and continued for 48 hours postoperatively) 43 .
Various other treatments aimed at prevention of persistent post-amputation pain have been studied. Peripheral perineural infusion is ineffective 44, 45 . Several epidural studies reporting positive results have significant methodological problems relating to small sample size and inadequate randomization or blinding [12] [13] [14] [15] . In a larger randomized, double-blind trial, Nikolajsen found lack of benefit from 18 hours of preoperative epidural bupivacaine and morphine in terms of reducing the incidence of both phantom and stump pain, when compared with preoperative oral or intramuscular opioids. Both groups received postoperative epidural analgesia 16 . Lambert and colleagues compared perioperative epidural infusion with perineural infusion 17 . The 63% incidence of phantom pain at six months in the epidural group was not significantly different from that in the perineural group or the natural history of the condition. The issue of the efficacy of preventative strategies therefore remains unresolved.
There are a number of possible explanations for our negative results, in addition to inadequate study power. Firstly, it could be argued that the high efficacy of PCA morphine used in both treatment and control groups could have overwhelmed any betweengroup difference. Opioids, as well as ketamine, modify sensory processing associated with central sensitization in the postoperative phase 39, 40 . However our results are at variance with those of Stubhaug 24 who, in a donor nephrectomy model, showed ketamine to be markedly more effective than opioids in reducing mechanical hyperalgesia around the wound.
A second possibility for our negative results relates to the existence of preoperative pain. The studies showing ketamine benefit in modulation of central sensitization in the postoperative phase 24, 40, 41 did not involve patients with significant preoperative pain. It may be that, in our study, the presence of preoperative pain was critical and the ketamine regimen we used, inadequate in the presence of an established process of central sensitization.
Third, there are questions relating to the dose of ketamine, its timing and the duration of infusion. Although ketamine provides consistent analgesia in the dose range of 0.3-0.5 mg.kg -1 .h -1 , the associated incidence of side-effects is high (20-30%) 46 . In the studies discussed above, lower doses of ketamine combined with opioids have been used to minimize side-effects, but results have been inconsistent in terms of opioid sparing effect and reduction in the allodynia and hyperalgesia. Our methodology was similar to Stubhaug 24 who used a pre-induction ketamine bolus dose of 0.5 mg.kg -1 followed by an infusion of 0.12 mg.kg -1 .h -1 for 24 hours and 0.06 mg.kg -1 .h -1 for a further 48 hours. Edwards undertook a dose-finding approach to the morphine ketamine combination 47 . Increasing central nervous system sideeffects were noted as the infusion rate was increased from 5 to 20 mg.h -1 . Our regimen of a pre-induction bolus of 0.5 mg.kg -1 and infusion of 0.15 mg.kg -1 .h -1 was a compromise between efficacy and unacceptable side-effects. It is possible that running the ketamine infusion for an additional 24 or 48 hours preoperatively may have improved efficacy.
A final possible factor impacting on our results was the lack of standardization of surgical technique. Many surgeons with differing levels of experience undertook the amputation surgery. It is unclear what effect surgical technique has on the incidence of postamputation pain.
Given that the process of central sensitization (as measured by allodynia index) was not modulated, it was predictable that there would be no significant difference in the incidence of post-amputation pain. However, a study with greater power is needed before a moderate ketamine effect on the incidence of phantom pain can be discounted. It is also possible that earlier initiation of ketamine may confer additional benefit. Other clinical measures of central sensitization may help to better define a possible correlation between acute neurophysiological change and progression to persistent pain.
